{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:31:11Z","timestamp":1775032271688,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While Sj\u00f6gren disease (SjD) overlap is known to modulate the clinical-serologic manifestations of other connective tissue diseases, the association with anti-synthetase syndrome (ASyS) has been seldom described in Caucasian cohorts. Anti-Ro52 autoantibodies, shared by both conditions, may blur early diagnostic attribution, particularly when glandular symptoms precede myositis-spectrum features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the clinical phenotype, serological profile, and disease trajectory of patients fulfilling classification criteria for both SjD and ASyS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicentre retrospective study (2018-2025) across three Italian referral centres, including patients meeting both the 2016 ACR\/EULAR SjD criteria and the Connor\u2019s\/provisional CLASS classification criteria for ASyS. Clinical features, serology, interstitial lung disease (ILD) characteristics, treatments, and outcomes were systematically collected. SjD activity was assessed using the ESSDAI and an adapted ESSDAI excluding the classic ASyS triad (pulmonary, articular and muscular domains).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen female patients of Caucasian ethnicity were identified. At the time of connective tissue disease diagnosis, 7 were classified as SjD and 10 received concomitant diagnoses; all reported early sicca symptoms. Regarding serology, anti-Ro52 antibodies were detected in all patients, most often (88%) in the absence of anti-Ro60 antibodies. Anti-synthetase antibodies were present in all cases, mainly non-Jo-1 specificities (77%), while anti-Jo-1 was observed in a minority of patients (23%). ILD was the leading organ involvement (14\/17, 82%), typically with acute\/subacute onset and NSIP or NSIP\/OP patterns. ILD drove treatment decisions and accounted for four deaths, whereas most survivors showed stabilization or mild improvement under immunosuppressive treatment. Systemic assessment indicated a predominantly ASyS-driven phenotype: although ESSDAI was moderately elevated (median 15, IQR 7.5-21), the adapted ESSDAI markedly decreased (median 5, IQR 0-6.5), reflecting limited SjD-specific systemic activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The SjD-ASyS overlap seem characterized by a coherent clinical-serological phenotype, defined by anti-Ro52-positive sicca presentation, non-Jo1 anti-ARS autoantibodies and early interstitial lung disease. Pulmonary involvement represents the main driver of disease course and outcomes in this subset. Recognition of this pattern may improve early identification of ASyS in Ro52-positive SjD presentations. Further prospective studies are warranted to clarify whether this subset reflects a distinct phenotype within the ASyS spectrum rather than a coincidental overlap of two independent diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1781334","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:40:21Z","timestamp":1775022021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond overlap: a Ro52-driven glandular-pulmonary phenotype at the interface of Sj\u00f6gren disease and anti-synthetase syndrome in a multicentre cohort"],"prefix":"10.3389","volume":"17","author":[{"given":"Gaetano","family":"La Rocca","sequence":"first","affiliation":[{"name":"Rheumatology Unit, University of Pisa, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ferro","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Pisa, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Morina","sequence":"additional","affiliation":[{"name":"Regional Referral Center for Rare Lung Disease, University of Catania, Department of Clinical and Experimental Medicine, Policlinico \u201cG. Rodolico-San Marco\u201d","place":["Catania, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pilato","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Rome, Department of Medicine, School of Medicine","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Rome, Department of Medicine, School of Medicine","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Fulvio","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Pisa, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Carli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Pisa, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Vancheri","sequence":"additional","affiliation":[{"name":"Regional Referral Center for Rare Lung Disease, University of Catania, Department of Clinical and Experimental Medicine, Policlinico \u201cG. Rodolico-San Marco\u201d","place":["Catania, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Sambataro","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Enna \u201cKore\u201d","place":["Enna, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Pisa, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Baldini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Pisa, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana","place":["Pisa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/3y0hqs","article-title":"Sj\u00f6gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison","volume":"40","author":"Baldini","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/o3pxq0","article-title":"Anticentromere antibody positive patients with primary Sj\u00f6gren's syndrome have distinctive clinical and immunological characteristics","volume":"41","author":"Liu","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152026","article-title":"Scleroderma-specific autoantibodies: Should they be included in the diagnostic work-up for Sj\u00f6gren's syndrome","volume":"55","author":"Marketos","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.2157","article-title":"Myositis in primary Sj\u00f6gren's syndrome: data from a multicentre cohort","volume":"33","author":"ColaFrancesco","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa257","article-title":"Refining myositis associated with primary Sj\u00f6gren's syndrome: data from the prospective cohort ASSESS","volume":"60","author":"Felten","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf566","article-title":"Clinical and molecular characterization of ILD in patients with overlapping ASyS and SjD: a retrospective observational study","volume":"65","author":"Qiu","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000001144","article-title":"Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.05.036","article-title":"Association of anti-Ro52 seropositive interstitial lung disease with a higher risk of disease progression and mortality","volume":"168","author":"Imai","year":"2025","journal-title":"Chest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738473","article-title":"TRIM21\/Ro52 - Roles in innate immunity and autoimmune disease","volume":"12","author":"Jones","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.3269","article-title":"The classification criteria for anti-synthetase syndrome (Class) project","volume":"76","author":"Giovanni Zanframundo","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210448","article-title":"Standardisation of labial salivary gland histopathology in clinical trials in primary Sj\u00f6gren's syndrome","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00101006","article-title":"ERS guidelines on the assessment of cough","volume":"29","author":"Morice","year":"2007","journal-title":"Eur Respir J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur Respir J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00152609","article-title":"A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis","volume":"36","author":"Nishiyama","year":"2010","journal-title":"Eur Respir J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483st","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am\u00a0J Respir Crit Care Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14155395","article-title":"Co-occurrence of anti-synthetase syndrome and Sj\u00f6gren disease: a case-based review","volume":"14","author":"Pilato","year":"2025","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1435525","DOI":"10.3389\/fimmu.2024.1435525","article-title":"Roles of TRIM21\/Ro52 in connective tissue disease-associated interstitial lung diseases","volume":"15","author":"Gong","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.43038","article-title":"Clinical characteristics of anti-synthetase syndrome: analysis from the classification criteria for anti-synthetase syndrome project","volume":"77","author":"Faghihi-Kashani","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164963","article-title":"Interstitial lung disease phenotypes and predictive risk factors in primary Sj\u00f6gren\u2019s syndrome","volume":"13","author":"La Rocca","year":"2024","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1265792","article-title":"Disease-specific autoantibody production in the lungs and salivary glands of anti-synthetase syndrome","volume":"15","author":"Takeshita","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1781334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:40:23Z","timestamp":1775022023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1781334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1781334"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1781334","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1781334"}}